|
業務類別
|
-- |
|
業務概覽
|
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities. |
| 公司地址
| 6 Tide Street, Suite 400, Boston, MA, USA, 02210 |
| 電話號碼
| +1 617 482-2333 |
| 傳真號碼
| +1 617 482-3337 |
| 公司網頁
| https://www.puretechhealth.com |
| 員工數量
| 56 |
| Mr. Michael Inbar |
Chief Accounting Officer |
-- |
30/04/2025 |
| Mr. Robert William Henry Lyne |
Chief Portfolio Officer |
-- |
30/04/2025 |
| Dr. Charles H. Sherwood, PhD |
General Counsel and Company Secretary |
-- |
30/04/2025 |
| Dr. Eric Elenko, PhD |
President |
-- |
30/04/2025 |
| Dr. Bharatt M. Chowrira |
Director and Chief Executive Officer |
美元 781.01K |
30/04/2025 |
|
|
| Ms. Sharon Barber-Lui |
Independent Director |
30/04/2025 |
| Dr. Michele A. M. Holcomb, PhD |
Independent Director |
30/04/2025 |
| Ms. Kiran Mazumdar-Shaw |
Independent Director |
30/04/2025 |
| Dr. Raju S. Kucherlapati |
Chairman of the Board |
30/04/2025 |
| Dr. Robert S. Langer, Sc.D. |
Director |
30/04/2025 |
| Dr. John L. LaMattina, PhD |
Senior Independent Director |
30/04/2025 |
| Dr. Bharatt M. Chowrira |
Director and Chief Executive Officer |
30/04/2025 |
|
|
|
|
